AIM ImmunoTech AIM
NYSE AIM
$0.17 +0.00 (+2.83%)
As of: Oct 21, 2026 · 1:34 PM EDT

AIM ImmunoTech (AIM) Current Debt (2018)

Updated

AIM ImmunoTech (AIM) reported Current Debt of -$2.21 million for FY2019, compared with -$1.96 million in FY2018.

Analysis

AIM ImmunoTech (AIM) Current Debt (2018) Analysis & Trends

  • According to Business Quant data, Current Debt came in at -$1.96 million in FY2018.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Current Debt (Qtr)
1 Eli Lilly 1,134.50 Bn 1,103.09 Bn 19.71 Bn 3.51 Bn
2 Johnson & Johnson 616.20 Bn 534.73 Bn 17.26 Bn -5.75 Bn
3 AbbVie 500.82 Bn 473.93 Bn 12.70 Bn -
4 Merck 367.31 Bn 321.69 Bn 12.21 Bn -
5 Novartis Ag 297.77 Bn 261.76 Bn 11.24 Bn 208.00 Mn
6 Astrazeneca 261.35 Bn 235.04 Bn 12.86 Bn -
7 Amgen 235.40 Bn 190.80 Bn 7.24 Bn -
8 Gilead Sciences 190.59 Bn 164.79 Bn 6.22 Bn -
9 Pfizer 169.39 Bn 116.04 Bn 10.94 Bn 64.00 Mn
10 AIM ImmunoTech 2.93 Mn -18.37 Mn 21,000.00 -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2018 -1.96 Mn
API Access

AIM ImmunoTech Current Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=current-debt&ticker=AIM&period=max&api_key=YOUR_API_KEY